$212.43
0.69% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Madrigal Pharmaceuticals, Inc. Stock price

$212.43
-42.38 16.63% 1M
-46.38 17.92% 6M
-18.95 8.19% YTD
+60.95 40.24% 1Y
+127.73 150.80% 3Y
+127.30 149.54% 5Y
+99.38 87.91% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-1.47 0.69%
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Key metrics

Market capitalization $4.64b
Enterprise Value $3.70b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 252.71
P/S ratio (TTM) P/S ratio 317.24
P/B ratio (TTM) P/B ratio 4.96
Revenue (TTM) Revenue $14.64m
EBIT (operating result TTM) EBIT $-530.28m
Free Cash Flow (TTM) Free Cash Flow $-450.82m
Cash position $1.06b
EPS (TTM) EPS $-25.50
P/E forward negative
P/S forward 46.07
EV/Sales forward 36.70
Short interest 24.89%
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

13x Buy
76%
3x Hold
18%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
76%
Hold
18%
Sell
6%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
15 15
-
100%
- Direct Costs 1.35 1.35
170% 170%
9%
13 13
2,758% 2,758%
91%
- Selling and Administrative Expenses 260 260
332% 332%
1,774%
- Research and Development Expense 283 283
5% 5%
1,934%
-530 -530
60% 60%
-3,617%
- Depreciation and Amortization 0.71 0.71
42% 42%
5%
EBIT (Operating Income) EBIT -530 -530
60% 60%
-3,622%
Net Profit -510 -510
55% 55%
-3,487%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
about one month ago
Madrigal Pharmaceuticals earned the first approval for a medicine in an area with a high unmet need. The biotech has more to do to dominate this market, considering it should become more crowded soon.
Neutral
The Motley Fool
about one month ago
Novo Nordisk just canceled one of its early-stage clinical programs. Madrigal Pharmaceuticals is a specialist developer for the same target illness.
Positive
Seeking Alpha
about 2 months ago
Madrigal Pharmaceuticals' Q2 2024 revenue from Rezdiffra exceeded expectations at $14.6 million. The company's SG&A expenses surged to $105.4 million, reflecting launch activities. Over 2,000 patients are currently on Rezdiffra, with broad insurance coverage.
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 376
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today